<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936061</url>
  </required_header>
  <id_info>
    <org_study_id>P-224011-0040</org_study_id>
    <nct_id>NCT04936061</nct_id>
  </id_info>
  <brief_title>Transnasal Cooling for Migraine</brief_title>
  <official_title>A Transnasal Evaporative Cooling Device for Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CoolTech LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CoolTech LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, double-blind, sham-controlled, randomized study to assess the safety,&#xD;
      tolerability, and optimal dose of the COOLSTAT Transnasal Thermal Regulating Device for acute&#xD;
      treatment of migraine. The hypothesis is that evaporative cooling induced by the CoolStat&#xD;
      using only ambient, dry air will reduce the pain and other symptoms of migraine headaches&#xD;
      during an acute migraine episode.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief</measure>
    <time_frame>2 hours</time_frame>
    <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to a mild headache or to no headache (Grade 1 or 0) at 2 hours after the CoolStat treatment session.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of the CoolStat device</measure>
    <time_frame>15 minutes</time_frame>
    <description>Number of subjects who fail to complete the full treatment session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of the CoolStat device</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of participants with device-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief</measure>
    <time_frame>0 minutes</time_frame>
    <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to a mild headache or to no headache (Grade 1 or 0) immediately after the CoolStat treatment session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief</measure>
    <time_frame>24 hours</time_frame>
    <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to a mild headache or to no headache (Grade 1 or 0) at 24 hours after the CoolStat treatment session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Freedom</measure>
    <time_frame>2 hours</time_frame>
    <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to no headache (Grade 0) at 2 hours after the CoolStat treatment session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Freedom</measure>
    <time_frame>24 hours</time_frame>
    <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to no headache (Grade 0) at 24 hours after the CoolStat treatment session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief from migraine-associated symptoms</measure>
    <time_frame>2 hours</time_frame>
    <description>The percentage of patients having a reduction in symptom severity from Grade 3/2 at baseline to Grade 1/0 at 2 hours post-treatment session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from migraine-associated symptoms</measure>
    <time_frame>2 hours</time_frame>
    <description>The percentage of patients with absence of photophobia, phonophobia, nausea and vomiting, at 2 hours after the end of the CoolStat treatment session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication</measure>
    <time_frame>2 to 24 hours</time_frame>
    <description>The percentage of patients who took acute anti-migraine medication between 2 and 24 hours after the end of the CoolStat treatment session.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Migraine</condition>
  <condition>Episodic Migraine</condition>
  <condition>Migraine With Aura</condition>
  <condition>Migraine Without Aura</condition>
  <arm_group>
    <arm_group_label>High flow treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low flow treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham flow ambient air</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>15 minute transnasal air flow therapy with the CoolStat sham device as an abortive treatment for migraine attack.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoolStat active device</intervention_name>
    <description>The CoolStat active device will administer a therapeutic flow of dry air into the nostril.</description>
    <arm_group_label>High flow treatment</arm_group_label>
    <arm_group_label>Low flow treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoolStat sham device</intervention_name>
    <description>The CoolStat sham device will administer a sham flow of ambient air into the nostril.</description>
    <arm_group_label>Sham flow ambient air</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meets the International Classification of Headache Disorders (ICHD-3) diagnostic&#xD;
             criteria for migraine with or without aura, with the exception of ''complicated&#xD;
             migraine'' (i.e., hemiplegic migraine, ophthalmoplegic migraine, migrainous&#xD;
             infarction).&#xD;
&#xD;
          2. Patient is between 18 and 80 years of age.&#xD;
&#xD;
          3. Patient experiences 2 to 8 migraine attacks per month.&#xD;
&#xD;
          4. Patient is in good reported general health, with no fever (&lt;38.3C/101F).&#xD;
&#xD;
          5. Patient has had diagnosis of migraine with or without aura over at least 1 year.&#xD;
&#xD;
          6. Migraine onset before 50 years of age.&#xD;
&#xD;
          7. Migraine prophylaxis medication unchanged for 6 weeks prior to study enrollment.&#xD;
&#xD;
          8. Able to attend treatment session within 6 hours of migraine onset, with 48 hours of&#xD;
             pain freedom prior to onset of migraine attack.&#xD;
&#xD;
          9. Migraine pain severity of Grade 2 or Grade 3 on day of treatment.&#xD;
&#xD;
         10. Provision of signed and dated informed consent form.&#xD;
&#xD;
         11. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. has difficulty distinguishing his or her migraine attacks from tension-type headaches&#xD;
&#xD;
          2. Patient has uncontrolled hypertension.&#xD;
&#xD;
          3. Patient has a fever (â‰¥38.3C / 101F).&#xD;
&#xD;
          4. Patient has used opioid medication or barbiturates in the past month.&#xD;
&#xD;
          5. Patient has Medication Overuse Headache (MOH), New Daily Persistent Headache (NDPH) or&#xD;
             Chronic Tension Type Headache (CTTH).&#xD;
&#xD;
          6. Patient has 15 or more headache days per month.&#xD;
&#xD;
          7. Patient has used acute treatment(s) for migraine in the 48 hours preceding treatment&#xD;
             i.e. over-the-counter (OTC) medications, prescription medications, or medical device).&#xD;
&#xD;
          8. Patient has received Botox treatment, supraorbital or occipital nerve blocks in the&#xD;
             last 4 weeks.&#xD;
&#xD;
          9. Intolerance to intranasal neurostimulation or sensory processing disorder that makes&#xD;
             the treatment not applicable.&#xD;
&#xD;
         10. Recurrent epistaxis or chronic rhinosinusitis.&#xD;
&#xD;
         11. Recent facial trauma, sinus or intranasal surgery within the last 4 months.&#xD;
&#xD;
         12. Known or suspected pregnancy.&#xD;
&#xD;
         13. Unable to fully understand the consent process and provide informed consent due to&#xD;
             either language barriers or mental capacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nauman Tariq, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atrium Health Neurosciences Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Casey Hannan</last_name>
    <phone>203-685-6352</phone>
    <email>channan@cooltechcorp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ximena Mouradian</last_name>
      <phone>517-303-3459</phone>
      <email>mouradi4@msu.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Charleston IV, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health Neurosciences Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keyerra Daniels</last_name>
      <phone>704-355-7823</phone>
      <email>Keyerra.Daniels@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Nauman Tariq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

